Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy.
暂无分享,去创建一个
M Duriez | B. Lévy | D. Heudes | P. Bruneval | A. Tedgui | P. Poitevin | A Tedgui | P Bruneval | P Poitevin | B. I. Lévy | D Heudes | B I Levy | B Corman | M. Duriez | B. Corman | B. Corman
[1] G. Jerums,et al. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.
[2] D. McCormack,et al. Inducible nitric oxide synthase and vascular reactivity in rat thoracic aorta: effect of aminoguanidine. , 1996, Journal of applied physiology.
[3] G. Striker,et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[4] K. Tracey,et al. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.
[5] L.,et al. Glucosylation of human collagen in aging and diabetes mellitus. , 1980, The Journal of clinical investigation.
[6] M. Huijberts,et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.
[7] D. Heudes,et al. Glomerular capillary network of cortical nephrons is reduced in male but not in female aging rats , 1996, Mechanisms of Ageing and Development.
[8] J. Guyton,et al. Comparison of aortic intima and inner media in young adult versus aging rats. Stereology in a polarized system. , 1983, The American journal of pathology.
[9] S. Krungkrai,et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Michel,et al. Instantaneous aortic blood flow measurement with range-gated Doppler flowmeter in anesthetized rat. , 1985, Journal of pharmacological methods.
[11] R. Bucala,et al. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[12] G. Ertl,et al. Ventricular remodeling after myocardial infarction. Experimental and clinical studies. , 1993, Basic research in cardiology.
[13] P. Verbeke,et al. Glycation of albumin with aging and diabetes in rats: changes in its renal handling , 1995, Mechanisms of Ageing and Development.
[14] Yong Ming Li,et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Mcdaniel,et al. Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.
[16] G. Norton,et al. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. , 1996, Circulation.
[17] K. Nicholls,et al. Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[18] R. Gerrity,et al. The aortic tunica intima in young and aging rats. , 1972, Experimental and molecular pathology.
[19] H. Yokoyama,et al. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[20] K. Yamada,et al. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. , 1994, Clinical nephrology.
[21] J. Michel,et al. Effect of Chronic Dihydropyridine (Isradipine) on the Large Arterial Walls of Spontaneously Hypertensive Rats , 1994, Circulation.
[22] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[23] M. Brownlee,et al. Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine , 1992, Diabetes.
[24] C. Wilson,et al. Renal vasodilatory response to intravenous glycine in the aging rat kidney. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[25] M. Jourdain,et al. On the positive charge and interface states in metal‐oxide‐semiconductor capacitors , 1996 .
[26] Z. Makita,et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.
[27] M. Mcdaniel,et al. Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.
[28] J. Kellum,et al. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. , 1994, Life sciences.
[29] G. Striker,et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Weisfeldt,et al. Effects of age, sex, and breeding status on the rat heart. , 1969, The American journal of physiology.
[31] R. Bucala,et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.